Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

linvoseltamab

A human, immunoglobulin G4 (IgG4) bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, linvoseltamab targets and binds to both CD3 on cytotoxic T lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-BCMA x anti-CD3 bispecific antibody REGN5458
anti-BCMA/CD3 bispecific antibody REGN5458
BCMA x CD3 bispecific antibody REGN5458
Foreign brand name:Lynozyfic
Code name:REGN 5458
REGN-5458
REGN5458
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search